Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells

Known as: Anti-CD3 x CD20Bi-Armed ATC 
Autologous activated T cells that have been coated with bispecific antibodies (BiAb), with potential antineoplastic and immunomodulating activities… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2014
01220112014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
PURPOSE This study reports a phase I immunotherapy trial in 23 women with metastatic breast cancer consisting of eight infusions… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
Targeting HER2 overexpressed breast cancer cells with anti‑HER2 monoclonal antibodies inhibits tumor growth. Here we investigated… (More)
Is this relevant?
2014
2014
A pilot phase I clinical trial involving 15 infusions of anti-CD3 × anti-CD20 bispecific Ab (CD20Bi)-armed anti-CD3-activated T… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Myeloid-derived suppressor cells (MDSCs) are one of the major components of the immune-suppressive network, play key roles in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Pancreatic cancer is a deadly disease and has the worst prognosis among almost all cancers and is in dire need of new and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
2548 Background: Nontoxic immunologic targeting strategies for the treatment of metastatic breast cancer (MBC) are needed. Anti… (More)
Is this relevant?